Anika Therapeutics Stock Alpha and Beta Analysis

ANIK Stock  USD 15.91  0.70  4.60%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Anika Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Anika Therapeutics over a specified time horizon. Remember, high Anika Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Anika Therapeutics' market risk premium analysis include:
Beta
1.03
Alpha
(0.06)
Risk
2.17
Sharpe Ratio
(0.04)
Expected Return
(0.08)
Please note that although Anika Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Anika Therapeutics did 0.06  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Anika Therapeutics stock's relative risk over its benchmark. Anika Therapeutics has a beta of 1.03  . Anika Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Anika Therapeutics is expected to follow. At this time, Anika Therapeutics' Tangible Book Value Per Share is quite stable compared to the past year. Price Book Value Ratio is expected to rise to 1.73 this year, although Enterprise Value Multiple is projected to rise to (21.94).

Enterprise Value

537.48 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Anika Therapeutics Backtesting, Anika Therapeutics Valuation, Anika Therapeutics Correlation, Anika Therapeutics Hype Analysis, Anika Therapeutics Volatility, Anika Therapeutics History and analyze Anika Therapeutics Performance.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Anika Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Anika Therapeutics market risk premium is the additional return an investor will receive from holding Anika Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Anika Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Anika Therapeutics' performance over market.
α-0.06   β1.03

Anika Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Anika Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Anika Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Anika Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Anika Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Anika Therapeutics shares will generate the highest return on investment. By understating and applying Anika Therapeutics stock market price indicators, traders can identify Anika Therapeutics position entry and exit signals to maximize returns.

Anika Therapeutics Return and Market Media

The median price of Anika Therapeutics for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 16.94 with a coefficient of variation of 4.27. The daily time series for the period is distributed with a sample standard deviation of 0.72, arithmetic mean of 16.88, and mean deviation of 0.63. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Disposition of 2491 shares by Anne Nunes of Anika Therapeutics subject to Rule 16b-3
12/16/2024
2
Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference
12/23/2024
3
Acquisition by David Colleran of 7662 shares of Anika Therapeutics subject to Rule 16b-3
12/24/2024
4
Global Viscosupplementation Market to Hit Valuation US 11.31 Billion By 2033 Astute Analytica
01/06/2025
5
Dimensional Fund Advisors LP Reduces Stake in Anika Therapeutics Inc
01/23/2025
6
Are Investors Undervaluing Anika Therapeutics, Inc. By 48
02/06/2025
7
Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference
02/25/2025
8
Avidity Biosciences, Inc. Reports Q4 Loss, Tops Revenue Estimates
02/27/2025
9
Anika Completes Divestiture of Parcus Medical
03/07/2025
10
Disposition of 20002 shares by Cheryl Blanchard of Anika Therapeutics subject to Rule 16b-3
03/10/2025
11
Anika Therapeutics to Release Earnings on Wednesday
03/11/2025
12
Microsoft To Rally More Than 17 Here Are 10 Top Analyst Forecasts For Thursday
03/13/2025

About Anika Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Anika or other stocks. Alpha measures the amount that position in Anika Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2022 2023 2024 2025 (projected)
Days Sales Outstanding80.978.7670.8854.36
PTB Ratio1.511.561.411.73

Anika Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Anika Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Anika Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Anika Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Anika Therapeutics. Please utilize our Beneish M Score to check the likelihood of Anika Therapeutics' management manipulating its earnings.
4th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Anika Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Anika Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Anika Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Anika Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...